Molecules that inhibit the synthesis of the ataxin 2 protein can ameliorate the effects of two neurodegenerative diseases in mouse models, raising hopes for the success of this approach in clinical trials. See Letters p.362 & p.367
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
References
Scoles, D. R. et al. Nature 544, 362–366 (2017).
Becker, L. A. et al. Nature 544, 367–371 (2017).
Pulst, S.-M. et al. Nature Genet. 14, 269–276 (1996).
Elden, A. C. et al. Nature 466, 1069–1075 (2010).
Sephton, C. F. et al. J. Biol. Chem. 285, 6826–6834 (2010).
Kiehl, T.-R. et al. Biochem. Biophys. Res. Commun. 339, 17–24 (2006).
Ramaswami, M., Taylor, J. P. & Parker, R. Cell 154, 727–736 (2013).
Finkel, R. S. et al. Lancet 388, 3017–3026 (2016).
Hua, Y. et al. Nature 478, 123–126 (2011).
DeVos, S. L. & Miller, T. M. Neurotherapeutics 10, 486–497 (2013).
Author information
Authors and Affiliations
Corresponding authors
Related links
Rights and permissions
About this article
Cite this article
Zhang, K., Rothstein, J. Two–for–one on potential therapies. Nature 544, 302–303 (2017). https://doi.org/10.1038/nature21911
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature21911